DDR2 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
This Target Evaluation Report for DDR2 is generated from PatSnap Life Sciences MCP data workflows, combining Target & Disease MCP biology context with Clinical Trials MCP validation and competitive signals.
For AI teams building biomedical agents, PatSnap Life Sciences MCP Servers provide structured retrieval across target biology, disease context, clinical trials, drug evidence, IP intelligence, and other R&D intelligence sources.
19 Direct drug records from Target & Disease MCP | 17 Development records in target context | 119 Disease associations captured | 404 Clinical trial records from Clinical Trials MCP |
Explore PatSnap Life Sciences MCP Servers for AI agents
Executive View
DDR2 is a collagen receptor tied to tissue remodeling and bone biology
Target & Disease MCP describes DDR2 as a fibrillar-collagen receptor involved in tissue remodeling, extracellular-matrix remodeling, differentiation, migration, proliferation, bone development, osteoblast differentiation, chondrocyte maturation, RUNX2 activation, MMP1/MMP2/MMP13 induction, fibroblast migration, wound healing, and tumor invasion.
Validation is early but biologically coherent
The MCP pull shows 19 direct drug records, 17 development records, and 119 disease associations. Clinical Trials MCP returned 404 records, reflecting both direct DDR2 interest and broader multikinase coverage.
Competition is less crowded but not empty
Sample trials include regorafenib combinations in GIST, QL1706 plus radiotherapy in HCC, and SH006 combination therapy versus regorafenib in HCC. These provide a directional competitive readout around kinase and stromal biology.
IP and strategy view
DDR2 IP should focus on fibrosis, collagen-rich tumor niches, bone/cartilage biology, and selectivity that avoids off-target kinase liabilities.
Clinical Validation and Competitive Landscape
Clinical Trials MCP returned 404 registered trial records connected to DDR2. The sample below is used as a directional competitive readout rather than a full regulatory review.
| Trial | Phase | Status |
|---|---|---|
| Regorafenib plus sintilimab and radiotherapy versus regorafenib in advanced GIST | Phase 3 | Not yet recruiting |
| Radiotherapy combined with iparomlimab and tuvonralimab in advanced unresectable HCC | Phase 2 | Not yet recruiting |
| SH006 combination therapy versus regorafenib in advanced HCC | Phase 2/3 | Not yet recruiting |
R&D Strategy Recommendation
DDR2 is a specialized remodeling target. It is most attractive when linked to collagen-rich disease biology, fibrosis, invasion, or skeletal biology with a clear biomarker plan.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers
